Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Advanced Metastatic Breast Cancer 1

Interventions

pembrolizumab 42Paclitaxel 26Cyclophosphamide 25Carboplatin 23olaparib 21Nivolumab 16fludarabine 15Docetaxel 13aldesleukin 12Gemcitabine 11Fulvestrant 11veliparib 9Bevacizumab 9sargramostim 8palbociclib 8durvalumab 8Trastuzumab 8Magnetic Resonance Spectroscopy 8liposomal doxorubicin 7atezolizumab 7Surveys and Questionnaires 7Ipilimumab 7Blood Specimen Collection 7niraparib 6avelumab 6Taxes 6Specimen Handling 6Interleukin-2 6Fluorouracil 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × vistusertib × Breast × Clear all
NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡